New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
08:12 EDTALNYAlnylam advances development candidate ALN-AAT
Alnylam Pharmaceuticals is advancing its Development Candidate for ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin in development for the treatment of AAT deficiency-associated liver disease. New pre-clinical data were presented in a Late-Breaking Abstract Session at Digestive Disease Week, held May 3 – 6, 2014 in Chicago, Illinois. ALN-AAT is one of Alnylam’s genetic medicine programs, which are RNAi therapeutics directed toward genetically defined targets for the treatment of diseases with high unmet medical need. AAT deficiency-associated liver disease is caused by accumulation of mutant AAT protein in liver tissue with subsequent liver injury, fibrosis, cirrhosis, and, in some cases, hepatocellular carcinoma. It is estimated that approximately 12,000 people with AAT deficiency in the U.S. and E.U. have associated liver pathology. The company now plans to initiate IND-enabling studies with the goal of filing an IND or IND equivalent for ALN-AAT in mid-2015.
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:32 EDTALNYJPMorgan Smid biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 21, 2015
11:01 EDTALNYAlnylam price target raised to $145 from $125 at Leerink
Subscribe for More Information
09:22 EDTALNYOn The Fly: Pre-market Movers
Subscribe for More Information
06:59 EDTALNYAlnylam to host conference call
Subscribe for More Information
06:03 EDTALNYAlnylam announces positive results from Phase 2 study with patisiran
Subscribe for More Information
April 20, 2015
07:18 EDTALNYAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 14, 2015
08:18 EDTALNYAlnylam data encouraging, says JMP Securities
Subscribe for More Information
April 13, 2015
11:02 EDTALNYAlnylam publishes pre-clinical results on ALN-AT3
Subscribe for More Information
10:15 EDTALNYHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use